Abstract 63P
Background
Melatonin (MT) regulates sleep and antioxidants while interacting with our microbiota. Advances in technology allow a deeper understanding of our microbiome and its environment. Research is now focused on plant-derived molecules, including sulforaphane (SFN), known for activating antioxidant responses through the Nrf2 pathway and inhibiting NF-κB. This knowledge paves the way for new research and potential treatment strategies, highlighting the potential of plant-derived molecules.
Methods
Our study observed decreased melatonin levels in 52 cancer patients with severe dysbiosis. This group also had reduced Lactobacillus acidophilus and saccharomyces boulardii. By culturing these microorganisms and adding melatonin, we saw an enhanced expression of the myrosinase gene (TGG1), and strong antiproliferative effects on cancer cultures. Our findings highlight melatonin's potential role in modulating microorganism behavior and managing dysbiosis in cancer patients.
Results
Our study found low melatonin (MT) levels in cancer patients, linked to decreased Lactobacillus acidophilus and saccharomyces boulardii levels. MT exposure enhanced myrosinase gene expression and showed antiproliferative effects on cancer cultures. The use of NO synthase inhibitor reduced SFN yield, yet MT counteracted this effect. This emphasizes MT's potential role in SFN synthesis regulation and cancer disease initiation. Particularly, in cancer patients, decreased SFN biosynthesis due to deficiency of these microorganisms and dysbiosis may increase oxidative stress, initiating cancerous conditions.
Conclusions
This finding has implications for understanding SFN synthesis regulation by NO and H2O2. Importantly, in cancer patients with a lack of Lactobacillus acidophilus and saccharomyces boulardii and MT deficiency, there's an increased risk of oxidative stress, creating conditions conducive to cancer. Unresolved is whether MT deficiency precedes the failure of these microorganisms and myrosinase gene inhibition, or if these conditions result from deep dysbiosis leading to MT deficiency.
Editorial acknowledgement
Thanks so much of our consultants from Tbilisi State Medical University:
Professor Gaiane Simonia and Professor Nana Okrostsvaridze
Clinical trial identification
Legal entity responsible for the study
Tbilisi State Medical University and Institute for Personalized Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract